Amiodarone and Electrical Cardioversion

Role in Electrical Cardioversion

• The European Society of Cardiology recommends amiodarone as the preferred antiarrhythmic agent for pre-treatment in patients with structural heart disease, heart failure, or when other agents are contraindicated, as it significantly increases the success rate of electrical cardioversion and prevents early recurrence of atrial fibrillation 1
• Amiodarone is superior to all other antiarrhythmic agents for maintaining sinus rhythm after cardioversion, with 83% of patients remaining in sinus rhythm at 6 months 3, 4, 5, 2

Patient Selection Algorithm

• The American College of Cardiology recommends amiodarone as the initial choice in patients with heart failure with reduced ejection fraction (LVEF ≤40%), severe left ventricular hypertrophy, coronary artery disease or previous myocardial infarction 1, 2, 8
• Amiodarone should be used cautiously as first-line in uncomplicated paroxysmal AF due to extracardiac toxicity risk, but it remains appropriate when other agents fail 3, 4

Mechanism of Benefit

• Amiodarone enhances cardioversion success through multiple mechanisms, including reversing atrial electrical remodeling, suppressing atrial ectopy, reducing electrical threshold, and providing rate control 5, 7, 9, 8, 2

Safety Profile

• The European Heart Journal reports that short-term amiodarone for cardioversion is well-tolerated with minimal serious adverse effects, and an 18% discontinuation rate occurs with long-term use, primarily due to extracardiac toxicity 3, 2